What are the main cardiac risks in the year after delivery?

The first year postpartum carries four distinct cardiovascular risks: (1) Peripartum cardiomyopathy (PPCM), heart failure that can develop up to 5 months postpartum, with peak onset between 1-3 months; (2) Postpartum hypertension, blood pressure can peak 3-6 days after delivery and remain elevated for weeks, highest risk in women who had preeclampsia or gestational hypertension; (3) Postpartum thyroiditis, affecting approximately 5-7% of women, causing transient hypo- or hyperthyroidism with palpitations, fatigue, and cardiac effects; (4) Elevated stroke risk, stroke risk remains elevated for 6-12 weeks after delivery, particularly in women who had hypertensive disorders.

What PPCM symptoms are worth reporting to a physician?

Shortness of breath at rest or with minimal exertion (difficulty climbing one flight of stairs); inability to lie flat to sleep (orthopnea); waking from sleep short of breath (paroxysmal nocturnal dyspnea); lower leg swelling that is new or progressively worsening after the first 2 weeks (not the normal postpartum edema that resolves in 1-2 weeks); sustained palpitations especially with lightheadedness; fatigue so severe that caring for an infant requires stopping and resting. These symptoms may be present within 1-5 months of delivery. They are often attributed to normal postpartum exhaustion. They require cardiac evaluation: at minimum BNP or NT-proBNP, ECG, and echocardiogram.

Is the 6-week postpartum visit adequate for cardiac monitoring?

No. The 6-week postpartum visit is the only scheduled medical contact for many postpartum women, but it occurs before the peak PPCM presentation window (most cases present 1-3 months postpartum, after the 6-week visit), often misses postpartum blood pressure that peaked at 3-6 days and may have already returned to normal by week 6, and rarely includes cardiovascular risk discussion for women who had pregnancy complications. The American Heart Association and ACOG both note the inadequacy of the single 6-week postpartum check for women who had cardiovascular complications or are at high risk. These women need monitoring at 2 weeks, 6 weeks, and 3 months minimum.

What do breastfeeding and prolactin do to the heart?

Prolactin, the hormone that drives breastfeeding, is one proposed mechanism in PPCM pathophysiology. The 16-kDa cleaved form of prolactin (produced from the parent molecule) promotes endothelial cell death and cardiac microvascular dysfunction. Bromocriptine, a prolactin inhibitor, is used in some centers (particularly in Europe and South Africa) to treat PPCM, with evidence that it improves left ventricular recovery in some patients. Whether breastfeeding worsens PPCM in the absence of the specific prolactin cleavage pathway is less clear; current guidelines do not universally recommend stopping breastfeeding in PPCM but note that the data is inconclusive. This is an active research area.

When should a woman with postpartum cardiac concerns see a cardiologist rather than her OB?

A cardiologist should be involved when: BNP or NT-proBNP is elevated above 100 pg/mL; echocardiogram shows reduced ejection fraction (below 50%) or diastolic dysfunction; blood pressure remains above 150/100 on antihypertensives; new-onset AF or arrhythmia is detected; or symptoms of dyspnea, orthopnea, or edema persist despite initial evaluation. The OB manages obstetric complications; the cardiologist manages cardiac function, medication optimization, and the long-term recovery plan if PPCM is diagnosed.

The Unseen Coronary

Post-Baby Cardiac: The Year After Delivery That Nobody Monitors

The cardiovascular risks of the first year after delivery are real and almost entirely unmonitored. Here is what that year actually looks like for the heart.

Job Mogire, MD, FACP, FACC · Medically reviewed June 17, 2026

She is three weeks postpartum. She cannot climb a flight of stairs without stopping. She is sleeping sitting up because lying flat makes her feel breathless. She has told three people she is not right, and all three have attributed it to the demands of a newborn.

Her left ventricular ejection fraction is 28%.

Peripartum cardiomyopathy (PPCM) presents in the last month of pregnancy or the first five months postpartum. Most cases present between 1-3 months postpartum, after the only scheduled postpartum visit most women receive. The symptom window falls into the gap where the obstetric team has signed off, the primary care physician is not yet engaged, and the new mother is expected to be tired.

The Mechanism

Pregnancy imposes a physiological load on the cardiovascular system that has no peacetime equivalent. Cardiac output rises 40-50% by the third trimester, driven by increased plasma volume, reduced systemic vascular resistance, and higher heart rate. The heart accommodates this by remodeling: the left ventricle dilates and hypertrophies. For most women, this reverses within weeks of delivery. For some, it does not.

The leading mechanistic hypothesis for PPCM centers on prolactin. Sliwa K et al. (European Heart Journal, 2006) demonstrated that postpartum oxidative stress promotes cleavage of the 26-kDa prolactin molecule into a 16-kDa fragment. Hilfiker-Kleiner D et al. (Cell, 2007) showed that this 16-kDa fragment is not benign: it suppresses VEGF signaling in cardiac microvascular endothelial cells, promotes apoptosis, and impairs the microvasculature on which cardiomyocytes depend for oxygenation. The cardiomyocytes, starved of vascular support, begin to fail. The result is a dilated, poorly contracting left ventricle in a woman who was otherwise healthy.

This is why bromocriptine, a prolactin inhibitor, has been studied as a treatment for PPCM, particularly in South Africa and Europe. The logic is direct: block the upstream hormone and reduce production of the damaging fragment. The evidence is promising but not yet definitive enough for universal guideline adoption in the United States.

Preeclampsia adds a second mechanism. The endothelial injury from preeclampsia is systemic and lasting. Circulating anti-angiogenic factors (sFlt-1 and sEng) suppress VEGF and TGF-beta signaling throughout the vasculature, including the coronary microcirculation. Combined with the hypercoagulable state of late pregnancy, which persists into the postpartum period, this creates the conditions for both cardiac and cerebrovascular events. The coagulation changes are not trivial: fibrinogen, factor VIII, and von Willebrand factor all remain elevated for weeks after delivery, explaining the measurably elevated stroke risk in the early postpartum weeks.

Postpartum thyroiditis follows a different pathway. The immune system is partially suppressed during pregnancy to prevent rejection of the fetal allograft. The postpartum rebound of immune surveillance can trigger autoimmune attack on the thyroid in women with underlying susceptibility (positive anti-TPO antibodies, personal or family history of thyroid disease). The resulting thyroid hormone fluctuations produce cardiac effects: tachycardia and atrial irritability in the hyperthyroid phase, bradycardia and reduced cardiac output in the hypothyroid phase.

5 / Solid

What the Evidence Shows

The incidence figures for PPCM carry significant racial disparity. Bello N and Arany Z (Circulation, 2015) estimated PPCM affects approximately 1 in 1,000-2,000 deliveries in the United States overall, but in Black women the rate approaches 1 in 300 in registry data from high-volume centers. The mechanisms behind this disparity are incompletely understood but likely involve higher rates of hypertensive disease of pregnancy, socioeconomic barriers to timely symptom evaluation, and possible genetic factors affecting the prolactin pathway.

Outcomes data from Kolte D et al. (Journal of the American College of Cardiology, 2014) examined over 34,000 PPCM hospitalizations in the United States. In-hospital mortality was 1.36%. Black women had significantly higher rates of mechanical ventilation, acute stroke, and cardiac arrest during hospitalization compared to white women. The study underscored that PPCM is not a uniformly benign condition and that delayed diagnosis contributes directly to worse outcomes.

Recovery of left ventricular function occurs in approximately 50-80% of women with PPCM. Recovery, when it happens, typically occurs within 6-12 months. Women who do not recover EF by 12 months are significantly less likely to recover thereafter and require long-term heart failure management. An LVEF <30% at diagnosis carries worse prognosis for recovery, though recovery can still occur.

On postpartum hypertension, Mehta LS et al. (American Heart Association Scientific Statement, 2019) explicitly noted that blood pressure peaks at 3-6 days postpartum in women with hypertensive disorders of pregnancy, frequently after hospital discharge. The statement recommends blood pressure evaluation at 3 days postpartum (by home monitoring or clinic visit) and again at 7-10 days for women who had preeclampsia, with immediate evaluation for readings above 150/100 mmHg.

The stroke risk data is sobering. Grandi SM et al. (BMJ, 2019) found that postpartum stroke risk peaks in the first week after delivery and remains elevated for up to 6 weeks, with an overall 2-3 fold increase compared to non-postpartum women of similar age. Women with preeclampsia carry approximately 3 times the absolute stroke risk of women with uncomplicated pregnancies in the postpartum period. Hemorrhagic and ischemic stroke are both elevated, reflecting the competing risks of hypertension and hypercoagulability in this window.

Postpartum thyroiditis affects approximately 5-7% of postpartum women in prospective studies, with higher rates (up to 25%) in women with type 1 diabetes or positive anti-TPO antibodies at delivery. Approximately 20-40% of affected women develop permanent hypothyroidism at 5-7 year follow-up, making this a diagnosis with long-term thyroid surveillance implications.

5 / Solid

Cardiologist's Note

The postpartum cardiovascular monitoring gap in the United States is a structural failure, not a personal failure of individual physicians. The obstetric team has managed the delivery; they consider their obligation largely complete. The primary care team has not yet re-engaged with a patient who may not see them for months. The cardiologist is not involved unless the primary care team makes a referral. The 6-week postpartum visit is cardiovascular medicine’s no-man’s-land: a single appointment covering wound healing, contraception, breastfeeding, and postpartum depression, with essentially no structured cardiovascular surveillance. For women who had hypertensive pregnancy, PPCM risk factors, or significant pregnancy complications, this is a gap that costs lives.

At the 6-week visit, I ask every patient with a hypertensive pregnancy history what their home blood pressure has been reading. Most have not been given a specific action threshold. The number I give them is 150/100 on two readings 30 minutes apart. That threshold triggers an ED visit, not a callback to my office, not a portal message, not waiting until the next available appointment. The postpartum period is not the time for ambiguity about when to seek emergency care. I also confirm they have a working home cuff, because many do not, and I ask them to bring their log to every visit for the next 12 months.

The hardest clinical problem in PPCM is distinguishing its fatigue from normal postpartum exhaustion. Both cause dyspnea on exertion. Both cause fatigue severe enough to impair function. The key features that raise my index of suspicion: fatigue that is worsening rather than stable or improving after the first two weeks; orthopnea (the need to sleep sitting up or propped at 45 degrees); paroxysmal nocturnal dyspnea; and lower extremity edema that persists or worsens beyond the second week postpartum. When any of these are present, the first test is a BNP or NT-proBNP. A BNP above 100 pg/mL in the postpartum period is not a finding to defer. It triggers an echocardiogram the same week. An LVEF <45% on echo confirms the diagnosis. The window between symptom onset and diagnosis is where we lose the most ground.

For women who are diagnosed with PPCM, I set explicit expectations about the recovery timeline at the first cardiology visit. Approximately 50-80% of women recover left ventricular function, defined as normalization of LVEF to at least 50-55%, within 6-12 months of diagnosis. Women with an LVEF <30% at diagnosis have a harder recovery curve, though recovery can still occur with guideline-directed medical therapy. I see these patients at 3-month intervals with repeat echocardiography until recovery is established or the 12-month mark. Women who have not recovered by 12 months need long-term heart failure management, genetic counseling regarding future pregnancies, and honest conversation about the risks of subsequent gestations. That conversation is difficult and important, and it belongs with a cardiologist who has tracked their trajectory, not in a 15-minute visit 6 months after the acute episode.

PPCM Treatment: The Medications and the Breastfeeding Question

Peripartum cardiomyopathy is treated with guideline-directed medical therapy for heart failure, with important modifications for the postpartum context. The standard heart failure medication regimen — beta-blockers, ACE inhibitors (or ARBs), and mineralocorticoid receptor antagonists — applies, but the choice of specific agents requires attention to breastfeeding and postpartum physiology.

Beta-blockers. Carvedilol and metoprolol succinate are the agents with the strongest evidence base in heart failure with reduced ejection fraction. In breastfeeding women, low-level beta-blocker transfer into breast milk occurs; metoprolol has lower relative infant dose than carvedilol and is generally considered compatible with breastfeeding by the American Academy of Pediatrics. The clinical priority is initiating beta-blockade for its survival benefit and LV remodeling effect. The breastfeeding discussion should be had with the treating cardiologist and a lactation consultant together, not deferred pending the feeding decision.

ACE inhibitors and ARBs. Both are contraindicated during pregnancy due to fetal renal toxicity. In the postpartum period, they are appropriate and important for their remodeling benefit in reduced EF heart failure. Enalapril has documented low breast milk levels and is a reasonable choice in breastfeeding women. Captopril similarly has limited infant exposure data and is used in some centers. ARBs have less postpartum safety data; most centers prefer ACE inhibitors in breastfeeding women with PPCM.

Mineralocorticoid receptor antagonists. Spironolactone and eplerenone improve outcomes in HFrEF. Spironolactone is not recommended in breastfeeding due to its anti-androgenic properties and limited safety data in infants. Eplerenone has less hormonal activity but minimal postpartum safety data. The cardiology team typically defers MRA initiation until the breastfeeding decision is made.

Bromocriptine. Bromocriptine, a dopamine agonist that suppresses prolactin secretion, is prescribed for PPCM in some centers — particularly in Europe and South Africa — based on the prolactin-cleavage hypothesis. The BLISS-PPC trial (Sliwa et al., European Heart Journal, 2010) showed higher rates of full cardiac recovery in the bromocriptine arm at 6 months compared to standard care alone. 4 / Promising Bromocriptine use requires stopping breastfeeding, which is a consequential decision. The 2019 European Society of Cardiology Heart Failure guidelines include bromocriptine as a IIb (may be considered) recommendation in PPCM for this reason. United States guidelines are more cautious, noting insufficient evidence for universal adoption. The conversation about bromocriptine in PPCM is one that belongs between the patient and a cardiologist who specializes in cardiac disease in pregnancy.

Future pregnancy risk. Women who have had PPCM and recovered full left ventricular function carry an estimated 20-25 percent risk of LVEF decline in a subsequent pregnancy, and approximately 7-10 percent risk of developing fulminant heart failure. Women who have not recovered LVEF should be strongly counseled against subsequent pregnancy, as the risk of death in a subsequent gestation is substantially higher. The Peripartum Cardiomyopathy National Registry data, analyzed by Elkayam and colleagues (NEJM, 2001), showed that among women with persistent LV dysfunction who became pregnant again, 44 percent experienced further deterioration, and there were deaths in the cohort. This information is not designed to foreclose reproductive options. It is the data women need to make informed choices about future pregnancies, and it belongs in the first cardiology visit after PPCM diagnosis.

What to Do This Week

Set up home blood pressure monitoring. Purchase an upper-arm cuff (not a wrist cuff) and measure blood pressure twice daily for the first 2 weeks postpartum, then as directed by your physician. Log the readings. Know your action threshold: 150/100 on two readings 30 minutes apart means go to the emergency department, not send a message.
Track your symptoms on paper. Write down your daily level of exertion and any breathlessness, swelling, palpitations, or sleep position changes (needing to sit up to breathe). Bring this log to every postpartum visit. A worsening trend over days is clinical signal. A stable or improving trend is reassurance. Without a written record, neither you nor your physician can distinguish the two.
Use specific language at your 6-week visit. “I had preeclampsia / gestational hypertension / gestational diabetes. I want this documented as a permanent cardiovascular risk modifier in my chart, and I want a plan for monitoring over the next 5 years.” And: “I have been more short of breath than expected. I would like a BNP and an echocardiogram to rule out peripartum cardiomyopathy.” Naming the tests specifically increases the probability of referral.
Know the emergency symptoms. Go to the emergency department without delay for: blood pressure above 150/100 on two readings; sudden severe headache described as the worst of your life; visual changes or blurred vision; one-sided weakness, facial drooping, or speech difficulty; shortness of breath at rest that is new or rapidly worsening; chest pain. These are not symptoms to manage with a portal message or a scheduled appointment.
Plan your follow-up beyond 6 weeks. Women with hypertensive pregnancy need blood pressure checks at 2 weeks, 6 weeks, and 3 months, with annual blood pressure monitoring for at least 5-7 years thereafter. Women with PPCM need echocardiographic follow-up at 3-month intervals until recovery. At 3 months postpartum, women with preeclampsia or gestational diabetes should have a cardiovascular baseline established: ApoB, Lp(a), hs-CRP, fasting insulin. These numbers, taken in the absence of pregnancy physiology, represent true baseline cardiovascular risk for the next decades.

The language matters at the 6-week visit. “I had preeclampsia. I want this in my chart as a cardiovascular risk modifier.” “I have been more short of breath than I expect. I would like a BNP to check for cardiomyopathy.” “My home blood pressure has been reading [X/Y]. What threshold should send me to the ED, and when should I return?” These sentences require a physician response. Framing symptoms as questions invites dismissal. Framing them as requests for specific tests or documented plans makes dismissal harder. The women most at risk for the conditions described in this article are also the most likely to have their symptoms attributed to the expected exhaustion of new motherhood. Specific requests for specific tests are the most reliable defense against that attribution.

Find out which signals are active in your own pattern.

Take the Women's Signal Check

Did this land?

The conversation

Join the men working through this in the open.